Screening Strategy for Metal Antitumor Agents Using Gold(III) Complexes
Author Information
Author(s): Simon P. Fricker
Primary Institution: AnorMED Inc.
Hypothesis
Compounds with selective activity against cell lines of a particular tissue type would be predictive for activity against the corresponding tumor.
Conclusion
Gold(III) complexes have shown activity against human tumor cells in both in vitro and in vivo test systems, suggesting they may represent a novel class of metal-based antitumor agents.
Supporting Evidence
- The gold(III) complexes were selectively active against human bladder and ovarian tumor cell lines in vitro.
- The acetato complex showed activity in experimental animal models of bladder and ovarian tumors.
- Gold(III) complexes exhibited a different biochemical mechanism from platinum-based drugs like cisplatin.
Takeaway
Scientists are testing new gold-based medicines to see if they can help fight cancer better than current treatments.
Methodology
The study involved in vitro screening of gold(III) complexes against human tumor cell lines and in vivo evaluation using xenografts in immune-deprived mice.
Limitations
The study primarily focused on in vitro and in vivo models, which may not fully predict human responses.
Want to read the original?
Access the complete publication on the publisher's website